By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.

Contact Information

Website: www.agenusbio.com
Email: investor@agenusbio.com
Main Phone: +1 781 674-4400
Address: 3 Forbes Road
State: MA
City / Town: Lexington
Country: US
Postal Code: 02421-7305

Issuer Information

Exchange: NSC
CEO: Garo H Armen
Employees: 359
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A